Alprazolam (Benzodiazepine)
Treatment for Anxiety Disorder
Typical Dosage: 0.25-4mg daily in divided doses
Effectiveness
80%
Safety Score
45%
Clinical Trials
35
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
0.25-4mg daily in divided doses
Time to Effect
Immediate
Treatment Duration
Short-term (2-4 weeks) or PRN
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$100
Side Effect Mgmt:$300
Total Annual:$550
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$110,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$786
Cost per Remission
$2,200
Comparison vs No Treatment
Cost Difference
+$550/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Alprazolam (Benzodiazepine) Outcomes
for Anxiety Disorder
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+70%
Remission Rate
+25%
Common Side Effects
Sedation
+40%
Dizziness
+25%
Dependence/Withdrawal
+30%
Cognitive impairment
+15%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
14 completed trials for Alprazolam (Benzodiazepine) in Anxiety Disorder
Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder
NCT00266409COMPLETEDPHASE4
418 participants
INTERVENTIONAL
Milwaukee, United States
Started: Oct 1, 2005
Pharmacokinetics Of Alprazolam Sublingual Tablet Versus Conventional Tablet
NCT01256151COMPLETEDPHASE1
28 participants
INTERVENTIONAL
New Haven, United States
Started: Jan 1, 2011
Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
NCT00662259COMPLETEDPHASE4
32 participants
INTERVENTIONAL
San Diego, United States
Started: Apr 1, 2008
PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)
NCT00703885COMPLETEDPHASE4
16 participants
INTERVENTIONAL
La Jolla, United States
Started: Jan 1, 2008
Bioequivalence Trial of Alprazolam 0.5 mg Tablets
NCT01745562COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Started: Dec 7, 2010
Bioequivalence Trial of Alprazolam 0.25 mg Tablets
NCT01853956COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Started: Dec 2, 2010
Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety
NCT00004373COMPLETEDPHASE2
80 participants
INTERVENTIONAL
San Antonio, United States
Started: Mar 1, 1997
Bioequivalence Trial of Alprazolam 2 mg Tablets
NCT01745575COMPLETEDPHASE1
26 participants
INTERVENTIONAL
Started: Mar 28, 2010
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
NCT00368745COMPLETEDPHASE3
108 participants
INTERVENTIONAL
San Pedro, Costa Rica +20 more
Started: Sep 1, 2006
Reassessment of Premedication in Surgery
NCT01549691COMPLETEDPHASE4
455 participants
INTERVENTIONAL
Cesson, France +7 more
Started: Mar 1, 2012
Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment
NCT00803400COMPLETEDPHASE4
150 participants
INTERVENTIONAL
Buenos Aires, Argentina
Started: Oct 1, 2008
A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
NCT00921063COMPLETEDPHASE2
222 participants
INTERVENTIONAL
Started: Nov 1, 2005
Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone
NCT01486615COMPLETEDPHASE4
80 participants
INTERVENTIONAL
Dharān, Nepal +1 more
Started: Oct 1, 2011
To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.
NCT00426608COMPLETEDPHASE1
20 participants
INTERVENTIONAL
Cambridge, United Kingdom
Started: Oct 6, 2006
Showing 20 of 35 total trials